We collaborate with referring providers to ensure that more patients can access the most advanced care and treatment available. Dana-Farber Brigham Cancer Center has a long history of utilizing cellular therapies to treat blood cancers and blood disorders. For over 50 years, we have performed more than 11,600 hematopoietic stem cell transplants—the original form of cellular therapy. We continue to offer patients the latest treatments, including CAR T-cell therapy, other genetically-modified T cells, and cancer vaccines.
Explore our history, progress, and innovation in adult stem cell transplantation.
Through partnering with you, we can help your patients receive their care closer to home, reducing the time and cost of care without sacrificing quality. Learn more about our unique approach, and how to refer your patients to our Stem Cell Transplantation and Cellular Therapies programs:
Program Accreditations, Registrations, and Licenses
- Foundation for the Accreditation of Cellular Therapy (FACT)
- U.S. Food and Drug Administration
- American Association of Blood Banks (AABB)
- Centers for Medicare and Medicaid Services
- The Joint Commission
- NMDP
Clinical and Research Affiliations
- Member of the Center for International Blood and Marrow Transplant Research (CIBMTR)
- Charter member of the Blood and Marrow Transplant Clinical Trials Network of the National Institutes of Health (BMT-CTN)
- Member of the Alliance for Clinical Trials in Oncology (formerly CALGB)
- Founding member of Dana-Farber/Harvard Cancer Center, designated a comprehensive cancer center by the National Cancer Institute
Clinical Education Opportunities
We offer observerships for physicians, mid-level practitioners, and nurses to shadow clinicians in the Hematologic Malignancies and Stem Cell Transplant departments. While observerships are overseen organizationally by Dana-Farber, curricula and scheduling are managed directly by each department. For hematologic malignancy and stem cell transplant observerships, email katie_kupferberg@dfci.harvard.edu.
In addition, as a principal teaching affiliate of Harvard Medical School, we share advances in cancer research and treatment with the health care community through continuing medical education (CME) and continuing educational unit (CEU) courses. Learn more about education and training opportunities.
